NSE IPO - Apply Online, Check Issue Date, Price, Lot Size & Allotment Status

Apply for NSE IPO:

Skip to main content

Live Outlook Therapeutics, Inc. Common Stock Share Price Chart

O H L

Outlook Therapeutics, Inc. Common Stock Performance Overview

Days Range
$0.67Low
$0.68High

Markets Today

Previous Close$0.68
Open$0.68
Volume469,833
Day's Range$0.67 - $0.68
52W Range$0.16 - $2.54
Market Cap$164.79 M

Historical Performance

1M Returns-2.71
3M Returns-56.90
6M Returns+94.57
1Y Returns-31.21
5Y Returns-98.59
10Y ReturnsNA

Outlook Therapeutics, Inc. Common Stock Fundamentals

Market Cap$164.79 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$1.41 M
ROE TTMN/A
EPS TTM$-0.87
Quarterly Earnings Growth YOYN/A
PB RatioN/A
EBITDA$-66.94 M
Profit Margin-4416.22
Market Cap$164.79 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$1.41 M
ROE TTMN/A
EPS TTM$-0.87
Quarterly Earnings Growth YOYN/A
PB RatioN/A
EBITDA$-66.94 M
Profit Margin-4416.22

Outlook Therapeutics, Inc. Common Stock Profit & Loss

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Total Revenue +$0$1.51 MN/A-$1.21 M$127.44 K$8.70 K
Gross Profit +$0$1.07 MN/A-$1.24 M-$21.89 K-$8.27 K
Operating Income -$12.39 M-$15.75 MN/A-$13.48 M-$14.03 M-$10.81 M
EBITDA -$12.36 M-$15.72 M$29.74 K-$13.45 M-$14.00 M-$10.80 M
Interest Expense $0-$49.35 KN/A$0$0$7
Depreciation $29.10 K$29.41 K-$30.07 K$30.42 K$13.79 K
Income Before Tax -$46.35 M-$20.15 MN/A-$23.06 M-$4.45 M-$20.32 M
Income Tax Expense $2.80 K$0N/A$0$0$0
Net Income +-$46.36 M-$20.15 MN/A-$23.06 M-$4.45 M-$20.32 M
Net Profit Margin --1338.75%-1909.05%-3494.28%-233554.85%

Outlook Therapeutics, Inc. Common Stock Financials Balance Sheet In USD

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Share Capital $329.07 K$434.79 K$538.87 K$645.57 K$1.05 M$1.87 M
Reserve & Surplus -$572.26 M-$592.42 M-$605.71 M-$628.77 M-$633.22 M-$653.54 M
Non-Current Liabilities $26.72 M$28.09 M$4.96 M$7.73 M$12.00 M$7.90 M
Current Liabilities $24.82 M$31.49 M$45.81 M$49.06 M$38.88 M$28.68 M
Total Liabilities $51.54 M$59.58 M$50.77 M$56.79 M$50.89 M$36.58 M
Fixed Assets $0$0$0$0$0$0
Current Assets $17.81 M$21.10 M$17.39 M$17.17 M$20.90 M$23.17 M
Total Assets $19.08 M$22.39 M$18.58 M$18.24 M$21.89 M$26.18 M

Outlook Therapeutics, Inc. Common Stock Cash Flow

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Net Income -$46.36 M-$20.15 M-$13.29 M-$23.06 M-$4.45 M-$20.32 M
Operating Cash Flow -$16.58 M-$11.90 M-$12.38 M-$14.94 M-$7.83 M-$21.01 M
Investing Cash Flow $0$0$0$0$0-$2.10 M
Financing Cash Flow $18.44 M$13.25 M$11.56 M$15.53 M$6.90 M$26.60 M
Change in Cash $1.85 M$1.34 M-$817.73 K$594.34 K-$929.20 K$3.49 M

Outlook Therapeutics, Inc. Common Stock Return Calculator

The Outlook Therapeutics, Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$141
Invested Amount$10,000
Est. Returns$-9,859
Invest in USA Stock Today

About Outlook Therapeutics, Inc. Common Stock

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

FAQs

Outlook Therapeutics, Inc. Common Stock (OTLK) share price as of September 18, 2026 is $0.68. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the Outlook Therapeutics, Inc. Common Stock (OTLK) Share by opening an international trading account with Angel One.
Purchasing Outlook Therapeutics, Inc. Common Stock (OTLK) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Outlook Therapeutics, Inc. Common Stock (OTLK) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of Outlook Therapeutics, Inc. Common Stock (OTLK) or any other US company shares in Angel One for any dollar amount.
The market capitalization of Outlook Therapeutics, Inc. Common Stock on September 18, 2026, is $164.79 M.
Outlook Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically in the Healthcare industry.
In order to invest in Outlook Therapeutics, Inc. Common Stock (OTLK) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.

Diversify Your Portfolio with US Stocks

Invest in Wall Street Giants from India

+91
Top US Stocks

VIEW ALL

Open Free Demat Account!

Join our 3.8 Cr+ happy customers
+91